New York, Jan. 09, 2018 -- According to the latest market report published by Persistence Market Research, titled “Nocturia Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026),” the global nocturia market is expected to expand at a CAGR of 7.5% during the forecast period 2017–2026. In 2017, the global market was valued at around US$ 2,500 Mn and is estimated to reach a valuation higher than US$ 4.5 Bn by the end of the forecast period.
Global Nocturia Market: Segmentation Forecast
The global nocturia market is segmented on the basis of indication type, drug type, distribution channel and region.
On the basis of indication type, the market is segmented into mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria and global polyuria. The low nocturnal bladder capacity segment is estimated to be the largest with a high market value and is projected to grow at a significant CAGR throughout the period of forecast. The nocturnal polyuria segment is projected to be the fastest growing and is expected to register a CAGR of 7.8% during the forecast period.
Global Nocturia Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/nocturia-market.asp
Based on drug type the market is segmented as anticholinergic drugs, desmopressin, antibiotics, antispasmodic and others. Desmopressin segment is poised to dominate the global market from a market value perspective. This segment reflected a market share of 31.6% in 2017, however it is expected to lose BPS by the end of the forecasted year.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. Hospital pharmacies is expected to hold major market share and registering CAGR of 8.1% in terms of value, over the forecast period owing to the increasing focus of availability. The online pharmacies segment is expected to gain high traction in the coming years and is projected to grow at a high CAGR of 8.4% during the period of forecast.
Request Sample Report@ https://www.persistencemarketresearch.com/samples/20806
On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia-Pacific, and the MEA. North America region led the nocturia market since past years and is likely to continue to dominate the overall market due to higher awareness and entry of players into the market by launching different products.
Companies are focusing on collaboration to develop new more effective products. The product type segment of nocturia will be boosted by its higher response rate and increasing research activities for R&D leading to inorganic growth.
Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/market-research/nocturia-market/toc
The global nocturia market is highly fragmented owing to the presence of various companies such as
- Allergan, Inc.
- Urigen Pharmaceuticals
- Ferring Pharmaceuticals
- Glenmark Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- AA Pharma Inc.
- Avadel Pharmaceuticals plc
- Others
Get full Report Now @ https://www.persistencemarketresearch.com/checkout/20806
Persistence Market Research Overview
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Mr. Rohit Bhisey Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [email protected] PMR Latest News: https://www.persistencemarketresearch.com/news


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Washington Post Publisher Will Lewis Steps Down After Layoffs
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



